IM Cannabis funds a shrinking business with converts while peers raise on scale and strategics
IM Cannabis's nine-month loss and shareholders' deficit sit against a week of financings in which strategic capital and clinical catalysts, not survival needs, set the terms.
What happened
IM Cannabis Corp. (IMCC) reported unaudited results to 30 September 2026 showing a nine-month net loss of C$13.9 million and revenue down to C$9.0 million. The asset base is smaller and the company still has a shareholders' deficit. The balance sheet was supported by fresh funding from convertible notes and a private placement. The material provided does not give the size or terms of either instrument, so the cost of that capital cannot be assessed here.
The pattern is a business whose revenue is contracting while it keeps raising external capital to stay funded. That is a different financing story from the others on the desk this week.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Sources
- IM Cannabis reports C$13.9M nine-month net loss as revenue slides to C$9.0M IM Cannabis Corp. · 13 Nov 2026
- Femasys Q3 2026: $30M private placement closed; U.S. sales flat, total sales fall 44.5% to $404,597 Femasys Inc · 13 Nov 2026
- Mingteng International, an automotive mold maker, prices $2.00/share registered direct offering with pre-funded warrants Mingteng International Corp Inc. · 13 Nov 2026
- Organigram to acquire Aurora Cannabis for about C$561M, backed by BAT private placement and ATB credit facilities Organigram Global Inc. · 13 Nov 2026
- Windward Bio prices Nasdaq IPO of 10.3 million shares at $17, targeting $225 million in gross proceeds Windward Bio Group AG · 12 Nov 2026
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.
Vir's Follow-On Tests Whether Open Equity Windows Favor Platform Stories Over Small-Cap Fixes
Vir Biotechnology's unpriced offering lands the same week as a $225M Windward IPO and a string of warrant-laden small-cap raises, showing how differently capital is available across biotech.
Tenon Medical's $15.6M raise clears convertibles and Nasdaq risk, but not the funding question
The SI joint fusion maker used a quarter of financing to repay senior notes early and regain listing compliance. Peers' Q3 raises show how different the small-cap capital market has become.
Femasys's $30M placement funds a U.S. launch and a pivotal trial as sales slip 44.5%
Femasys closed a $30M private placement to build a FemaSeed sales team and run the FemBloc pivotal trial. Q3 sales fell 44.5%, and the financing market around it is split between large IPOs and small, structured raises.